An Effective Immunosuppressant with Significant Safety Considerations: Pharmacists’ Guide to Safe Use of Mycophenolate

This educational activity is sponsored by Postgraduate Healthcare Education, LLC (PHE). This activity is supported by an independent educational grant from the Mycophenolate REMS Group.

This activity is intended to be fully compliant with the Mycophenolate REMS education requirements issued by the U.S. Food and Drug Administration (FDA).

Registration & Dates for Activities

November 12, 2024
2:00-3:00 PM ET

December 4, 2024
3:00-4:00 PM ET

FACULTY

Cher Y. Enderby, PharmD, EMBA, BCPS, BCNSP, FASHP, FFSHP
Manager, Education & Staff Development
Mayo Clinic
Jacksonville, FL

Mary M. Chandran, PharmD, CPP, BCTXP, BCPS, FAST, FACCP
Clinical Pharmacist Practitioner, Solid Organ Transplant
University of North Carolina (UNC) Health
Chapel Hill, NC

FINANCIAL DISCLOSURE

Dr. Enderby has no relevant affiliations or financial relationships with a commercial interest to disclose.

Dr. Chandran has disclosed that she has received honoraria for non-CME related activities from Eurofins Viracor.

The clinical reviewer, Lisa Holle, PharmD, BCOP, FHOPA has no actual or potential conflicts of interest in relation to this program.

Susanne Kwas, MSHF, BSN, RN, Robin Soboti, RPh, and Susan R. Grady, MSN, RN, as well as the planners, managers, and other individuals, not previously disclosed, who are in a position to control the content of Postgraduate Healthcare Education (PHE) continuing education (CE) activities hereby state that they have no relevant conflicts of interest and no financial relationships or relationships to products or devices during the past 12 months to disclose in relation to this activity. PHE is committed to providing participants with a quality learning experience and to improve clinical outcomes without promoting the financial interests of a proprietary business.

All relevant financial relationships have been mitigated.

ACCREDITATION STATEMENTS

PHARMACY
Postgraduate Healthcare Education, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
UAN: 0430-0000-24-105-L01-P
Credits: 1.0 hour (0.1 ceu)

Type of Activity: Application
Media: Internet

Fee Information: There is no fee. This is a free continuing education activity.
Estimated time to complete activity: 60 minutes

TARGET AUDIENCE

Pharmacists who do or may encounter patients being prescribed or on a mycophenolic acid product.

HOW TO OBTAIN CREDIT

Participants must 1) read the learning objectives and faculty disclosures; 2) attend and participate in the live webinar; and 3) complete the evaluation form directly after the event with a maximum of within 60 days of attending the live session. To answer the questions, click on your selected choice for each answer then proceed to the next question. To receive Credit, you must provide your date of birth and NABP number. All Credit information will be uploaded into CPE monitor within 30 days.

GOAL

The goal of this educational activity is to educate pharmacists in all practice settings nationwide on the mechanism and uses of mycophenolate, the risks associated with using the drug in females of reproductive potential, and the importance of adherence to the Mycophenolate REMS program to improve safe use of the drug.

LEARNING OBJECTIVES

At the conclusion of the activity, pharmacists and pharmacy technicians will be able to:

• Describe the mechanism of action and uses of mycophenolate
• Review the risks of miscarriage and congenital malformations associated with mycophenolate use during pregnancy
• Apply strategies for safe use of mycophenolate in females of reproductive potential in accordance with the Mycophenolate REMS program

REQUIRED COMPUTER HARDWARE/SOFTWARE

Please ensure the computer system you plan to use meets the following minimum requirements:

• Operating System: Windows 98 or higher & Macintosh 2.2 or higher
• Internet Browser (Mac & Windows): Internet Explorer 6.0 or higher, Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher, & Opera 5 or higher
• Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible
• Peripherals: Computer speakers or headphones
• Monitor Screen Resolution: 320 x 480 or higher
• Media Viewing Requirements: Adobe Reader, Microsoft PowerPoint, Flash Player & HTML5

Disclosure of Unlabeled Use and Disclaimer

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Postgraduate Healthcare Education, LLC, or the Mycophenolate REMS Group/U.S. FDA. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions, and possible contraindications on dangers in use, (review of any applicable manufacturer's product information) and comparison with recommendations of other authorities.

The author, sponsor, and publisher of this continuing education activity have made all reasonable efforts to ensure that all information contained herein is accurate in accordance with the latest available scientific knowledge at the time of acceptance for publication. However, because information regarding drugs (their administration, dosages, contraindications, adverse reactions, interactions, special warnings, precautions, etc.) is subject to constant change, the reader is advised to check the manufacturer's package insert for information concerning recommended dosages and potential problems and cautions prior to dispensing or administering the drug. Special precautions should be taken when a drug is new, or highly toxic, or is unfamiliar to the dispenser or administrant. This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the U.S. Food and Drug Administration (FDA). Neither the publisher nor sponsor promotes the use of any agent outside of approved labeling. Statements made in this activity have not been evaluated by the FDA.